Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs CARBAGLU
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Carbaglu (carbonic anhydrase inhibitor) reduces intraocular pressure by inhibiting carbonic anhydrase in the ciliary processes, thereby decreasing aqueous humor secretion.
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Adjunctive treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
100 mg/kg (up to 200 mg/kg) intravenous infusion over 90 minutes, followed by 100 mg/kg/day continuous intravenous infusion; maintenance: 100 mg/kg/day oral divided into 2-4 doses, not to exceed 20 g/day.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Terminal half-life approximately 5.8 hours in adults; prolonged in hepatic impairment (up to 10 hours).
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Metabolized via hepatic glucuronidation and renal excretion; not extensively metabolized by CYP450 enzymes.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Primarily renal excretion (97% unchanged) with minimal biliary/fecal elimination (<3%).
Low protein binding; 0–11% bound, primarily to albumin.
Negligible (<1% bound to albumin or other plasma proteins).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Vd approximately 0.3 L/kg, indicating distribution primarily in extracellular fluid.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Oral bioavailability approximately 30% (range 20-40%) due to first-pass metabolism; IV bioavailability 100%.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific dose adjustment is provided in the manufacturer's labeling; use with caution in renal impairment. GFR <30 m L/min: consider alternative therapy.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
No specific adjustment is recommended for hepatic impairment per labeling; monitor transaminases.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Loading dose: 100 mg/kg (up to 200 mg/kg) IV over 90 minutes; continuous infusion: 100-200 mg/kg/day IV or oral divided q4-6h; maximum 20 g/day.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
No specific adjustments; use lowest effective dose and monitor renal function given age-related decline.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Sulfonamide derivative; may cause serious, potentially fatal reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and agranulocytosis. Discontinue at first sign of rash or other hypersensitivity.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Sulfonamide hypersensitivity: may cause serious skin reactions and blood dyscrasias; discontinue if rash or signs of hypersensitivity occur.,May cause metabolic acidosis; use caution in patients with respiratory acidosis, diabetes, or electrolyte disturbances.,May cause drowsiness, dizziness, or blurred vision; caution when driving or operating machinery.
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Hypersensitivity to carbonic anhydrase inhibitors or sulfonamides,Severe renal impairment (Cr Cl <10 m L/min),Adrenocortical insufficiency (Addison's disease),Severe hepatic insufficiency
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
No specific food interactions; however, patients with urea cycle disorders often require protein restriction. For Carbaglu, avoid acidic beverages (e.g., fruit juice) as they may degrade the drug. Administer with water only.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
First trimester: Limited human data; animal studies show no increased risk of malformations. Second/third trimester: No known fetal harm; can be used for NAGS deficiency.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No human data; M/P ratio unknown. Use with caution.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
No specific dose adjustments required; monitor ammonia levels to guide therapy.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Carbaglu (carglumic acid) is a structural analog of N-acetylglutamate (NAG) and acts as a replacement therapy for N-acetylglutamate synthase (NAGS) deficiency. It is also used for hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). Monitor ammonia levels closely; therapeutic goal is normalization within 24 hours. Administer via oral or nasogastric tube; dissolve tablets in water and administer immediately. Do not mix with acidic fluids (e.g., fruit juice) as stability may be affected. May cause headaches, vomiting, and fever. For NAGS deficiency, lifelong treatment is required. For PA/MMA, use is acute and short-term. Not effective for other urea cycle disorders.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
Take Carbaglu exactly as prescribed; do not skip doses.,Dissolve the tablet(s) in a small amount of water (2.5 m L per tablet) and drink immediately. Do not mix with juice or other acidic beverages.,If using a nasogastric tube, ensure the solution is given right after preparation.,Monitor for signs of high ammonia (e.g., lethargy, vomiting, irritability) and report to doctor immediately.,Keep all appointments for blood tests to check ammonia levels.,Store tablets at room temperature (20-25°C), away from moisture and light.,Inform your doctor of all other medications, especially valproic acid (may decrease effectiveness).
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs CARBAGLU, answered by our medical review team.
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. CARBAGLU is a Ammonia Detoxicant that works by Carbaglu (carbonic anhydrase inhibitor) reduces intraocular pressure by inhibiting carbonic anhydrase in the ciliary processes, thereby decreasing aqueous humor secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and CARBAGLU depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. The standard adult dose of CARBAGLU is: 100 mg/kg (up to 200 mg/kg) intravenous infusion over 90 minutes, followed by 100 mg/kg/day continuous intravenous infusion; maintenance: 100 mg/kg/day oral divided into 2-4 doses, not to exceed 20 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and CARBAGLU in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. CARBAGLU is classified as Category C. First trimester: Limited human data; animal studies show no increased risk of malformations. Second/third trimester: No known fetal harm; can be used for NAGS deficiency.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.